234 related articles for article (PubMed ID: 23164935)
1. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
[TBL] [Abstract][Full Text] [Related]
2. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
3. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.
Zhou J; Swiderski P; Li H; Zhang J; Neff CP; Akkina R; Rossi JJ
Nucleic Acids Res; 2009 May; 37(9):3094-109. PubMed ID: 19304999
[TBL] [Abstract][Full Text] [Related]
4. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
5. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
6. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-targeted RNAi for HIV-1 therapy.
Zhou J; Rossi JJ
Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
[TBL] [Abstract][Full Text] [Related]
8. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.
Neff CP; Zhou J; Remling L; Kuruvilla J; Zhang J; Li H; Smith DD; Swiderski P; Rossi JJ; Akkina R
Sci Transl Med; 2011 Jan; 3(66):66ra6. PubMed ID: 21248316
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.
Zhou J; Neff CP; Liu X; Zhang J; Li H; Smith DD; Swiderski P; Aboellail T; Huang Y; Du Q; Liang Z; Peng L; Akkina R; Rossi JJ
Mol Ther; 2011 Dec; 19(12):2228-38. PubMed ID: 21952167
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-siRNA chimeras for HIV.
Takahashi M; Burnett JC; Rossi JJ
Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
[TBL] [Abstract][Full Text] [Related]
11. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
Zhou J; Rossi J
J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
Zhou J; Rossi JJ
BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
[TBL] [Abstract][Full Text] [Related]
13. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
14. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
15. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.
Pang KM; Castanotto D; Li H; Scherer L; Rossi JJ
Nucleic Acids Res; 2018 Jan; 46(1):e6. PubMed ID: 29077949
[TBL] [Abstract][Full Text] [Related]
18. Intracellular delivery of RNA-based therapeutics using aptamers.
Thiel KW; Giangrande PH
Ther Deliv; 2010 Dec; 1(6):849-61. PubMed ID: 21643487
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Dicer Knockout on RNA Interference Using Various Dicer Substrate Small Interfering RNA (DsiRNA) Structures.
Song MS; Alluin J; Rossi JJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327991
[TBL] [Abstract][Full Text] [Related]
20. Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3' Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs.
Zhou J; Song MS; Jacobi AM; Behlke MA; Wu X; Rossi JJ
Mol Ther Nucleic Acids; 2012 Apr; 1(4):e17. PubMed ID: 23343928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
